CHARLES RIVER LABORATORIES (CRL) Stock Fundamental Analysis
USA - NYSE:CRL - US1598641074 - Common Stock
153.21 USD
-2.18 (-1.4%)
CRL gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 56 industry peers in the Life Sciences Tools & Services industry. CRL has an average financial health and profitability rating. CRL is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
CRL had positive earnings in the past year.
In the past year CRL had a positive cash flow from operations.
In the past 5 years CRL has always been profitable.
In the past 5 years CRL always reported a positive cash flow from operatings.
1.2 Ratios
CRL has a Return On Assets of -0.92%. This is comparable to the rest of the industry: CRL outperforms 58.93% of its industry peers.
CRL's Return On Equity of -2.06% is in line compared to the rest of the industry. CRL outperforms 57.14% of its industry peers.
CRL's Return On Invested Capital of 5.72% is fine compared to the rest of the industry. CRL outperforms 73.21% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for CRL is significantly below the industry average of 15.41%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.92% | ||
| ROE | -2.06% | ||
| ROIC | 5.72% |
ROA(3y)4.11%
ROA(5y)4.9%
ROE(3y)9.94%
ROE(5y)12.5%
ROIC(3y)7.32%
ROIC(5y)7.6%
1.3 Margins
CRL's Profit Margin has declined in the last couple of years.
CRL's Operating Margin of 11.64% is fine compared to the rest of the industry. CRL outperforms 69.64% of its industry peers.
In the last couple of years the Operating Margin of CRL has remained more or less at the same level.
Looking at the Gross Margin, with a value of 35.03%, CRL is doing worse than 62.50% of the companies in the same industry.
In the last couple of years the Gross Margin of CRL has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11.64% | ||
| PM (TTM) | N/A | ||
| GM | 35.03% |
OM growth 3Y-8.72%
OM growth 5Y-1.4%
PM growth 3Y-71.55%
PM growth 5Y-51.64%
GM growth 3Y-2.67%
GM growth 5Y-1%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), CRL is destroying value.
Compared to 1 year ago, CRL has less shares outstanding
CRL has more shares outstanding than it did 5 years ago.
The debt/assets ratio for CRL has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 2.24 indicates that CRL is not a great score, but indicates only limited risk for bankruptcy at the moment.
CRL has a Altman-Z score (2.24) which is comparable to the rest of the industry.
CRL has a debt to FCF ratio of 4.04. This is a neutral value as CRL would need 4.04 years to pay back of all of its debts.
CRL has a better Debt to FCF ratio (4.04) than 69.64% of its industry peers.
CRL has a Debt/Equity ratio of 0.70. This is a neutral value indicating CRL is somewhat dependend on debt financing.
CRL has a Debt to Equity ratio of 0.70. This is in the lower half of the industry: CRL underperforms 75.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.7 | ||
| Debt/FCF | 4.04 | ||
| Altman-Z | 2.24 |
ROIC/WACC0.57
WACC10.05%
2.3 Liquidity
A Current Ratio of 1.36 indicates that CRL should not have too much problems paying its short term obligations.
CRL has a Current ratio of 1.36. This is in the lower half of the industry: CRL underperforms 78.57% of its industry peers.
CRL has a Quick Ratio of 1.10. This is a normal value and indicates that CRL is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of CRL (1.10) is worse than 80.36% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.36 | ||
| Quick Ratio | 1.1 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 4.49% over the past year.
Measured over the past years, CRL shows a quite strong growth in Earnings Per Share. The EPS has been growing by 8.93% on average per year.
CRL shows a decrease in Revenue. In the last year, the revenue decreased by -1.21%.
The Revenue has been growing by 9.09% on average over the past years. This is quite good.
EPS 1Y (TTM)4.49%
EPS 3Y-0.03%
EPS 5Y8.93%
EPS Q2Q%11.43%
Revenue 1Y (TTM)-1.21%
Revenue growth 3Y4.59%
Revenue growth 5Y9.09%
Sales Q2Q%0.59%
3.2 Future
CRL is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.95% yearly.
Based on estimates for the next years, CRL will show a small growth in Revenue. The Revenue will grow by 2.43% on average per year.
EPS Next Y-1.01%
EPS Next 2Y2.26%
EPS Next 3Y4.23%
EPS Next 5Y5.95%
Revenue Next Year-1.06%
Revenue Next 2Y0.54%
Revenue Next 3Y2.17%
Revenue Next 5Y2.43%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 14.31, the valuation of CRL can be described as correct.
94.64% of the companies in the same industry are more expensive than CRL, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of CRL to the average of the S&P500 Index (27.38), we can say CRL is valued slightly cheaper.
CRL is valuated correctly with a Price/Forward Earnings ratio of 14.20.
Based on the Price/Forward Earnings ratio, CRL is valued cheaply inside the industry as 89.29% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of CRL to the average of the S&P500 Index (22.86), we can say CRL is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.31 | ||
| Fwd PE | 14.2 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, CRL is valued cheaply inside the industry as 98.21% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, CRL is valued cheaply inside the industry as 94.64% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.03 | ||
| EV/EBITDA | 10.9 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)1.6
EPS Next 2Y2.26%
EPS Next 3Y4.23%
5. Dividend
5.1 Amount
CRL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NYSE:CRL (9/22/2025, 2:05:17 PM)
153.21
-2.18 (-1.4%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners111.57%
Inst Owner Change1.14%
Ins Owners0.91%
Ins Owner Change6.07%
Market Cap7.54B
Analysts69.57
Price Target182.1 (18.86%)
Short Float %5.49%
Short Ratio3.06
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.56%
Min EPS beat(2)11.44%
Max EPS beat(2)23.68%
EPS beat(4)4
Avg EPS beat(4)11.21%
Min EPS beat(4)4.03%
Max EPS beat(4)23.68%
EPS beat(8)8
Avg EPS beat(8)10.55%
EPS beat(12)12
Avg EPS beat(12)8.62%
EPS beat(16)16
Avg EPS beat(16)6.82%
Revenue beat(2)2
Avg Revenue beat(2)3.59%
Min Revenue beat(2)3.45%
Max Revenue beat(2)3.74%
Revenue beat(4)4
Avg Revenue beat(4)2.63%
Min Revenue beat(4)0.91%
Max Revenue beat(4)3.74%
Revenue beat(8)7
Avg Revenue beat(8)1.68%
Revenue beat(12)10
Avg Revenue beat(12)1.88%
Revenue beat(16)11
Avg Revenue beat(16)1.12%
PT rev (1m)10.72%
PT rev (3m)16.01%
EPS NQ rev (1m)-0.09%
EPS NQ rev (3m)-1.19%
EPS NY rev (1m)0%
EPS NY rev (3m)5.4%
Revenue NQ rev (1m)0.19%
Revenue NQ rev (3m)2.93%
Revenue NY rev (1m)0.07%
Revenue NY rev (3m)2.34%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.31 | ||
| Fwd PE | 14.2 | ||
| P/S | 1.87 | ||
| P/FCF | 13.03 | ||
| P/OCF | 9.57 | ||
| P/B | 2.25 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.9 |
EPS(TTM)10.71
EY6.99%
EPS(NY)10.79
Fwd EY7.04%
FCF(TTM)11.76
FCFY7.67%
OCF(TTM)16
OCFY10.44%
SpS81.87
BVpS68.14
TBVpS-3.77
PEG (NY)N/A
PEG (5Y)1.6
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.92% | ||
| ROE | -2.06% | ||
| ROCE | 7.24% | ||
| ROIC | 5.72% | ||
| ROICexc | 5.88% | ||
| ROICexgc | 13.43% | ||
| OM | 11.64% | ||
| PM (TTM) | N/A | ||
| GM | 35.03% | ||
| FCFM | 14.36% |
ROA(3y)4.11%
ROA(5y)4.9%
ROE(3y)9.94%
ROE(5y)12.5%
ROIC(3y)7.32%
ROIC(5y)7.6%
ROICexc(3y)7.59%
ROICexc(5y)7.91%
ROICexgc(3y)18.25%
ROICexgc(5y)19.94%
ROCE(3y)9.27%
ROCE(5y)9.62%
ROICexcg growth 3Y-14.69%
ROICexcg growth 5Y-4.68%
ROICexc growth 3Y-7.59%
ROICexc growth 5Y-3.19%
OM growth 3Y-8.72%
OM growth 5Y-1.4%
PM growth 3Y-71.55%
PM growth 5Y-51.64%
GM growth 3Y-2.67%
GM growth 5Y-1%
F-Score4
Asset Turnover0.53
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.7 | ||
| Debt/FCF | 4.04 | ||
| Debt/EBITDA | 2.59 | ||
| Cap/Depr | 48.58% | ||
| Cap/Sales | 5.19% | ||
| Interest Coverage | 4.15 | ||
| Cash Conversion | 87.57% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.36 | ||
| Quick Ratio | 1.1 | ||
| Altman-Z | 2.24 |
F-Score4
WACC10.05%
ROIC/WACC0.57
Cap/Depr(3y)90.89%
Cap/Depr(5y)85.95%
Cap/Sales(3y)7.21%
Cap/Sales(5y)6.76%
Profit Quality(3y)1669.68%
Profit Quality(5y)1049.89%
High Growth Momentum
Growth
EPS 1Y (TTM)4.49%
EPS 3Y-0.03%
EPS 5Y8.93%
EPS Q2Q%11.43%
EPS Next Y-1.01%
EPS Next 2Y2.26%
EPS Next 3Y4.23%
EPS Next 5Y5.95%
Revenue 1Y (TTM)-1.21%
Revenue growth 3Y4.59%
Revenue growth 5Y9.09%
Sales Q2Q%0.59%
Revenue Next Year-1.06%
Revenue Next 2Y0.54%
Revenue Next 3Y2.17%
Revenue Next 5Y2.43%
EBIT growth 1Y-25.61%
EBIT growth 3Y-4.53%
EBIT growth 5Y7.56%
EBIT Next Year28.55%
EBIT Next 3Y12.77%
EBIT Next 5Y10.95%
FCF growth 1Y99.92%
FCF growth 3Y-1.94%
FCF growth 5Y8.06%
OCF growth 1Y25.98%
OCF growth 3Y-1.16%
OCF growth 5Y8.84%